仙琚制药
(002332)
| 流通市值：91.17亿 | | | 总市值：91.60亿 |
| 流通股本：9.85亿 | | | 总股本：9.89亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,008,198,242.3 | 4,000,693,148.05 | 3,237,007,358.82 | 2,137,847,609.83 |
| 营业收入 | 1,008,198,242.3 | 4,000,693,148.05 | 3,237,007,358.82 | 2,137,847,609.83 |
| 二、营业总成本 | 843,841,353.08 | 3,310,485,780.21 | 2,606,344,910.38 | 1,730,317,120.59 |
| 营业成本 | 450,032,933.28 | 1,700,842,559.24 | 1,468,589,836.32 | 965,397,843.09 |
| 税金及附加 | 6,806,845.23 | 35,214,121.58 | 24,008,593.36 | 16,615,958.48 |
| 销售费用 | 248,285,768.31 | 1,033,752,829.44 | 726,212,046.7 | 488,133,098.5 |
| 管理费用 | 70,687,334 | 309,786,244.07 | 226,132,174.54 | 158,809,744.66 |
| 研发费用 | 70,771,880.3 | 265,172,350.8 | 184,732,549.63 | 124,956,369.27 |
| 财务费用 | -2,743,408.04 | -34,282,324.92 | -23,330,290.17 | -23,595,893.41 |
| 其中:利息费用 | 148,326.07 | 3,132,732.94 | 1,386,946.1 | 937,734.73 |
| 其中:利息收入 | 3,645,082.1 | 29,475,160.84 | 24,443,304.43 | 19,079,749.68 |
| 加:投资收益 | -5,784,141.64 | -8,135,977.92 | 12,752,065.24 | 17,896,454.71 |
| 资产处置收益 | 1,796.42 | 283,085.44 | -730,693.12 | 61,575.16 |
| 资产减值损失(新) | - | -43,509,998.98 | -23,570,905.19 | -24,220,044.58 |
| 信用减值损失(新) | -4,057,083.2 | -11,445,758.77 | -7,696,654.31 | -5,223,685.32 |
| 其他收益 | 4,099,037.51 | 50,812,521.56 | 19,310,961.76 | 13,313,639.93 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 158,616,498.31 | 678,211,239.17 | 630,727,222.82 | 409,358,429.14 |
| 加:营业外收入 | 514,956.35 | 28,960,528.04 | 1,728,550.84 | 1,703,041.14 |
| 减:营业外支出 | 1,251,381.66 | 208,844,571.9 | 4,745,380.25 | 3,938,275.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 157,880,073 | 498,327,195.31 | 627,710,393.41 | 407,123,195.07 |
| 减:所得税费用 | 19,716,284.23 | 98,403,980.63 | 85,012,851.21 | 59,447,304.32 |
| 六、净利润 | 138,163,788.77 | 399,923,214.68 | 542,697,542.2 | 347,675,890.75 |
| 持续经营净利润 | 138,163,788.77 | 399,923,214.68 | 542,697,542.2 | 347,675,890.75 |
| 归属于母公司股东的净利润 | 143,983,992.29 | 397,178,995.31 | 530,180,818.31 | 339,722,437.63 |
| 少数股东损益 | -5,820,203.52 | 2,744,219.37 | 12,516,723.89 | 7,953,453.12 |
| (一)基本每股收益 | 0.15 | 0.4 | 0.54 | 0.34 |
| (二)稀释每股收益 | 0.15 | 0.4 | 0.54 | 0.34 |
| 八、其他综合收益 | 46,221,040.19 | -64,136,651.01 | -5,397,470.36 | -32,585,815.58 |
| 归属于母公司股东的其他综合收益 | 46,221,040.19 | -64,136,651.01 | -5,397,470.36 | -32,585,815.58 |
| 九、综合收益总额 | 184,384,828.96 | 335,786,563.67 | 537,300,071.84 | 315,090,075.17 |
| 归属于母公司股东的综合收益总额 | 190,205,032.48 | 333,042,344.3 | 524,783,347.95 | 307,136,622.05 |
| 归属于少数股东的综合收益总额 | -5,820,203.52 | 2,744,219.37 | 12,516,723.89 | 7,953,453.12 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |